99 related articles for article (PubMed ID: 20564348)
1. Members of the low-density lipoprotein receptor-related proteins provide a differential molecular signature between parental and CD133+ DAOY medulloblastoma cells.
Annabi B; Doumit J; Plouffe K; Laflamme C; Lord-Dufour S; Béliveau R
Mol Carcinog; 2010 Jul; 49(7):710-7. PubMed ID: 20564348
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype.
Srivastava VK; Nalbantoglu J
Cytometry A; 2008 Oct; 73(10):940-8. PubMed ID: 18773455
[TBL] [Abstract][Full Text] [Related]
3. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia.
Blazek ER; Foutch JL; Maki G
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):1-5. PubMed ID: 17084552
[TBL] [Abstract][Full Text] [Related]
4. Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype.
Annabi B; Rojas-Sutterlin S; Laflamme C; Lachambre MP; Rolland Y; Sartelet H; Béliveau R
Mol Cancer Res; 2008 Jun; 6(6):907-16. PubMed ID: 18567795
[TBL] [Abstract][Full Text] [Related]
5. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
6. Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells.
Cox JL; Wilder PJ; Desler M; Rizzino A
PLoS One; 2012; 7(8):e44087. PubMed ID: 22937156
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
8. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
[TBL] [Abstract][Full Text] [Related]
9. Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells.
Roudi R; Ebrahimi M; Sabet MN; Najafi A; Nourani MR; Fomeshi MR; Samadikuchaksaraei A; Shariftabrizi A; Madjd Z
Future Oncol; 2015; 11(17):2383-93. PubMed ID: 26285774
[TBL] [Abstract][Full Text] [Related]
10. Embryonic Stem Cell-Related Protein L1TD1 Is Required for Cell Viability, Neurosphere Formation, and Chemoresistance in Medulloblastoma.
Santos MC; Silva PB; Rodini CO; Furukawa G; Marco Antonio DS; Zanotto-Filho A; Moreira JC; Okamoto OK
Stem Cells Dev; 2015 Nov; 24(22):2700-8. PubMed ID: 26159230
[TBL] [Abstract][Full Text] [Related]
11. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases.
Boivin D; Labbé D; Fontaine N; Lamy S; Beaulieu E; Gingras D; Béliveau R
Biochemistry; 2009 May; 48(18):3998-4007. PubMed ID: 19296573
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein.
Osmond TL; Broadley KW; McConnell MJ
Int J Mol Med; 2010 Jun; 25(6):883-8. PubMed ID: 20428792
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
14. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
15. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma.
Nakai E; Park K; Yawata T; Chihara T; Kumazawa A; Nakabayashi H; Shimizu K
Cancer Invest; 2009 Nov; 27(9):901-8. PubMed ID: 19832037
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypomethylation regulates CD133 expression in human gliomas.
Tabu K; Sasai K; Kimura T; Wang L; Aoyanagi E; Kohsaka S; Tanino M; Nishihara H; Tanaka S
Cell Res; 2008 Oct; 18(10):1037-46. PubMed ID: 18679414
[TBL] [Abstract][Full Text] [Related]
17. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation.
He H; Nilsson CL; Emmett MR; Marshall AG; Kroes RA; Moskal JR; Ji Y; Colman H; Priebe W; Lang FF; Conrad CA
J Proteome Res; 2010 May; 9(5):2098-108. PubMed ID: 20199106
[TBL] [Abstract][Full Text] [Related]
18. Expression and regulation of AC133 and CD133 in glioblastoma.
Campos B; Zeng L; Daotrong PH; Eckstein V; Unterberg A; Mairbäurl H; Herold-Mende C
Glia; 2011 Dec; 59(12):1974-86. PubMed ID: 21901757
[TBL] [Abstract][Full Text] [Related]
19. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
Yan X; Ma L; Yi D; Yoon JG; Diercks A; Foltz G; Price ND; Hood LE; Tian Q
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1591-6. PubMed ID: 21220328
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
